Chad Terhune
@chadterhune
Followers
11K
Following
29
Media
50
Statuses
37K
Health reporter @Reuters. Previously at WSJ, LA Times, KHN. @UFJSchool alum. Tips: [email protected] or DM for Signal (he/him)
Los Angeles
Joined December 2011
🔊 A mother opens up about the freedom, challenges, and costs of long-term medication for her son, who has struggled with obesity for years. Listen on this special episode of Reuters World News podcast with @cwalljasper, @chadterhune and @robinrespaut
https://t.co/3JkowjWq5z
7
4
8
🔊 Is lifelong medication the answer for some teens struggling with obesity? Experts and parents weigh in — listen now on this special episode of the Reuters World News podcast with @cwalljasper, @chadterhune and @robinrespaut
https://t.co/WNLx4atYTG
1
3
7
🔊 Families face tough choices when treating childhood obesity — from chronic illness and unknown side effects to high costs and shifting insurance coverage. Hear their perspective with @cwalljasper, @chadterhune and @robinrespaut
https://t.co/wBmEz9M3wA
6
3
14
🔊 On a special episode of Reuters World News, we sit down with a pediatric obesity specialist to understand the role of powerful new weight loss drugs in combating childhood obesity. Listen now with @cwalljasper, @chadterhune and @robinrespaut
https://t.co/uyxyWlWJS1
3
1
12
🔊 Young people struggling with weight often face relentless bullying and mental health challenges. New medications offer the possibility of life-changing results but come with an uncertain future. Listen with @cwalljasper, @chadterhune and @robinrespaut
https://t.co/8O9uJ0c6TW
5
5
13
🔊 Hear from a parent taking the leap to help her child fight obesity with new medications. Don’t miss this special episode of Reuters World News podcast with @cwalljasper, @chadterhune and @robinrespaut
https://t.co/sshca6jsFq
2
4
11
🔊 One teen shares his obesity-journey. Hear how weight-loss drugs are offering life-changing results but with unknown long-term effects. @chadterhune and @robinrespaut discuss with @cwalljasper on this special episode of Reuters World News podcast https://t.co/x9Z0G9chnE
3
5
12
🔊 Doctors are split on the long-term impact of weight-loss drugs for teens vs. the benefits of slimming down. Learn more on this special episode of Reuters World News podcast with @cwalljasper @chadterhune and @robinrespaut
https://t.co/lVgOQx0rCn
1
4
12
Pediatricians are seeing more teens with type2 diabetes and liver disease due to rising rates of obesity. Now, weight-loss drugs could slow them. Listen to this special episode of Reuters World News podcast with @cwalljasper, @chadterhune and @robinrespaut
https://t.co/jknAMSldLv
12
10
19
Exclusive: FDA to request Sarepta to stop all shipments of gene therapy Elevidys, source says @BhanviSatija
reuters.com
U.S. regulators asked Sarepta Therapeutics on Friday to voluntarily halt shipments of its Elevidys gene therapy after a muscular dystrophy patient who received a different, experimental treatment...
0
1
2
ICYMI: This is our deep dive into the lives of four teens who are at the forefront of a monumental shift in the treatment of childhood #obesity. Meet Austin, Katie, Leo and Stephanie: https://t.co/qt7vbU9YlH
@longreads #GLP1 #weightloss
reuters.com
Reuters delves into the experiences of four American teenagers with obesity who were among the first wave to take Novo Nordisk’s weight-loss drug.
0
0
2
My latest story: New data show most patients now stay on Wegovy, Zepbound after a year, reversing prior trends #obesity #GLP1
reuters.com
Nearly two-thirds of patients who started on weight-loss drugs Wegovy or Zepbound last year were still taking them a year later, according to an analysis of U.S. pharmacy claims.
0
0
0
Watch this powerful video where teens describe the challenges they face from #obesity and how medical treatment played out for them. Full story @reuters
https://t.co/Z0BgSPdErV
#GLP1
0
0
0
For my latest story, we spent more than a year closely following four teens and their families to examine in detail the impact of #obesity treatment with the new GLP-1 drugs #pediatrics #health
reuters.com
Reuters delves into the experiences of four American teenagers with obesity who were among the first wave to take Novo Nordisk’s weight-loss drug.
0
0
0
Kennedy's new vaccine adviser was expert witness against Merck vaccine https://t.co/8UzwKzHWsd
@Reuters @FedcourtJunkie @chadterhune
reuters.com
One of the new vaccine advisers picked by U.S. Health Secretary Robert F. Kennedy Jr. has earned thousands of dollars as an expert witness in litigation against Merck’s Gardasil vaccine, court...
1
5
19
Great coverage by @chadterhune of @Reuters on what's happening with the vaccines advisory committee (ACIP). I preview work we've done on conflict of interest trends in ACIP. @USCPrice @USCSchaeffer
https://t.co/3Y2MVuJ6O2
reuters.com
Robert F. Kennedy Jr. faced questions from Congress about his own potential conflicts of interest during a confirmation hearing.
1
1
5
Exclusive: Kennedy's new vaccine adviser was expert witness against Merck vaccine
reuters.com
One of the new vaccine advisers picked by U.S. Health Secretary Robert F. Kennedy Jr. has earned thousands of dollars as an expert witness in litigation against Merck’s Gardasil vaccine, court...
0
3
3
The Public Integrity Section is not filing new cases. Its staff has been reduced from more than 30 attorneys to four. And its role reviewing potential cases against members of Congress has been suspended. By me, @nedmparker1 @byPeterEisler and @AGoudsward
https://t.co/K7lj7sKn96
reuters.com
Stripped of its authority and nearly all its staff, the U.S. Justice Department’s storied Public Integrity Section is on life support. Former prosecutors say the overhaul could make it easier to...
7
85
85
Wegovy use among US teens up 50% as obesity crisis worsens https://t.co/AqUZk1pYeb via @chadterhune & @RobinRespaut
reuters.com
American teens are increasingly turning to the weight-loss drug Wegovy as more families and their doctors gain confidence in its use for young people with obesity, new data shared with Reuters shows.
0
1
0